Item 7.01 Regulation FD Disclosure

On January 26, 2023, Monopar Therapeutics Inc. issued a press release announcing it is planning to report over the next two months (1) the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, (2) clinical data from its camsirubicin Phase 1b trial, and (3) a preclinical progress update on its MNPR-101 RIT program.

The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference

Item 9.01 Financial Statements and Exhibits







Exhibit No.   Description
  99.1          Press Release Dated January 26, 2023





2

© Edgar Online, source Glimpses